Anaplastic thyroid cancer: a case series study
Vol. 69 No. 2 (2023), ORIGINAL ARTICLES. C. CLINICAL RESEARCH
Vol. 69 No. 2 (2023)

Anaplastic thyroid cancer: a case series study

ORIGINAL ARTICLES. C. CLINICAL RESEARCH
https://doi.org/10.37469/0507-3758-2023-69-2-253-258
Published 30.04.2023
Pavel Isaev
A. Tsyb MRRC- Branch of the NMRRC of the Ministry of Health of the Russian Federation. 2 NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0001-9831-4814
Viatcheslav Polkin
A. Tsyb MRRC- Branch of the NMRRC of the Ministry of Health of the Russian Federation. 2 NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0003-0857-321X
Alexey Ilyin
A. Tsyb MRRC- Branch of the NMRRC of the Ministry of Health of the Russian Federation. 2 NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0002-6581-633X
Natalia Severskaya
A. Tsyb MRRC- Branch of the NMRRC of the Ministry of Health of the Russian Federation. 2 NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0002-9426-8459
Alice Plugar
A. Tsyb MRRC- Branch of the NMRRC of the Ministry of Health of the Russian Federation. 2 NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0002-0049-4309
Sergey Podvyaznikov
N.N. Blokhin NMRCO
https://orcid.org/0000-0003-1341-0765
Sergei Ivanov
NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0001-7689-6032
Andrei Kaprin
NMRRC of the Ministry of Health of the Russian Federation.
https://orcid.org/0000-0001-8784-8415
pdf (Русский)

Keywords

anaplastic thyroid cancer

How to Cite

Isaev, P., Polkin, V., Ilyin, A., Severskaya, N., Plugar , A., Podvyaznikov, S., Ivanov, S., & Kaprin, A. (2023). Anaplastic thyroid cancer: a case series study. Voprosy Onkologii, 69(2), 253–258. https://doi.org/10.37469/0507-3758-2023-69-2-253-258
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

We conducted a retrospective analysis of the treatment of anaplastic thyroid cancer (ATC) in 24 patients between May 2014 and July 2021. The study included 24 patients aged 22 to 81 years, 15 (62.5 %) female and 9 (37.5 %) male. Among them, 14 (58.3 %) underwent surgical treatment. In the postoperative period, 8 (33.3 %) patients received a course of radioiodine therapy with a total dose (TD) of 3-4 GBq. Seven (29.2 %) patients underwent external beam radiation therapy (EBRT), while in 2 (8.3 %) cases, chemotherapy (CT) with carboplatin was administered concomitantly with EBRT. Four (16.7%) patients were treated with lenvatinib. Nine (37.5 %) patients did not receive treatment due to various reasons. In untreated patients, overall survival (OS) was 5.8 ± 0.5 months. For patients who received treatment, OS was 9.6 ± 1.0 months. P <0.00095.

https://doi.org/10.37469/0507-3758-2023-69-2-253-258
pdf (Русский)

References

Bible KC, Kebebew E, Brierley J, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337–86. doi:10.1089/thy.2020.0944.

Maniakas A, Zafereo M, Cabanillas ME. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am. 2022;51(2):391–401. doi:10.1016/j.ecl.2021.11.020.

Ranganath R, Shah MA, Shah AR. Anaplastic thyroid cancer. Current Opinion in Endocrinology, Diabetes & Obesity. 2015;22(5):387–91. doi:10.1097/MED.0000000000000189.

Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation. 2016;126(3):1052–66. doi:10.1172/jci85271.

Latteyer S, Tiedje V, König K, et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine. 2016;54(3):733–41. doi:10.1007/s12020-016-1080-9.

Tiedje V, Ting S, Herold T, et al. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget. 2017;8(26):42613–20. doi:10.18632/oncotarget.17300.

Aldinger KA, Samaan NA, Ibanez M, et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer. 1978;41(6):2267-75. doi:10.1002/1097-0142(197806)41:6<2267::aid-cncr2820410627>3.0.co;2-7.

Zhang Z, Liu D, Murugan AK, et al. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014;21(2):161-73. doi:10.1530/ERC-13-0399.

Lee J, Hwang JA, Lee EK. Recent progress of genome study for anaplastic thyroid cancer. Genomics Inform. 2013;11(2):68-75. doi:10.5808/GI.2013.11.2.68.

Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. 2013;18(8):926-32. doi:10.1634/theoncologist.2013-0072.

Li Y, Zhang J, Zhou H, Du Z. Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review). Oncol Rep. 2022;48(3):156. doi:10.3892/or.2022.8368.

Haymart MR, Banerjee M, Yin H, et al. Marginal treatment benefit in anaplastic thyroid cancer. Cancer. 2013;119(17):3133-9. doi:10.1002/cncr.28187.

Orita Y, Sugitani I, Amemiya T, et al. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150(6):1212-9. doi:10.1016/j.surg.2011.09.005.

Wendler J, Kroiss M, Gast K, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. 2016;175(6):521529. doi:10.1530/EJE-16-0574.

Dralle H, Musholt TJ, Schabram J, et al. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398(3):34775. doi:10.1007/s00423-013-1057-6.

Goffredo P, Thomas SM, Adam MA, et al. Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases. Ann Surg Oncol. 2015;22(13):4166-74. doi:10.1245/s10434-015-4742-6.

Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2017;123(9):1653-1661. doi:10.1002/cncr.30493.

Dumke AK, Pelz T, Vordermark D. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol. 2014;9:90. doi:10.1186/1748-717X-9-90.

Lowe NM, Loughran S, Slevin NJ, et al. Anaplastic thyroid cancer: the addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival--a single centre experience and review of the literature. Scientific World Journal. 2014:674583. doi:10.1155/2014/674583.

Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20(1):7-14. doi:10.1089/thy.2009.0115.

Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232-40. doi:10.1089/thy.2013.0078.

Marten KA, Gudena VK. Use of vemurafenib in anaplastic thyroid carcinoma: a case report. Cancer Biol Ther. 2015;16(10):1430-3. doi:10.1080/15384047.2015.1071734.

Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf v600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7-13. doi:10.1200/JCO.2017.73.6785.

Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25. doi:10.3389/fonc.2017.00025.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2023

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.